» Articles » PMID: 11282020

Phosphoinositide 3-kinase Signalling Pathways

Overview
Journal J Cell Sci
Specialty Cell Biology
Date 2001 Apr 3
PMID 11282020
Citations 187
Authors
Affiliations
Soon will be listed here.
Abstract

Phosphoinositide 3-kinases (PI3Ks) phosphorylate the 3'-OH position of the inositol ring of inositol phospholipids, producing three lipid products: PtdIns(3)P, PtdIns(3,4)P(2) and PtdIns(3,4,5)P(3). These lipids bind to the pleckstrin homology (PH) domains of proteins and control the activity and subcellular localisation of a diverse array of signal transduction molecules. Three major classes of signalling molecule are regulated by binding of D-3 phosphoinositides to PH domains: guanine-nucleotide-exchange proteins for Rho family GTPases, the TEC family tyrosine kinases such as BTK and ITK in B and T lymphocytes, respectively, and the AGC superfamily of serine/threonine protein kinases. These molecules are activated by a variety of extracellular stimuli and have been implicated in a wide range of cellular processes, including cell cycle progression, cell growth, cell motility, cell adhesion and cell survival.

Citing Articles

Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma.

Zheng K, Jin G, Cao R, Gao Y, Xu J, Chai R Cancer Chemother Pharmacol. 2025; 95(1):21.

PMID: 39792198 PMC: 11723846. DOI: 10.1007/s00280-024-04748-3.


Molecular mechanisms involved in therapeutic effects of natural compounds against cisplatin-induced cardiotoxicity: a review.

Hesari M, Mohammadi P, Moradi M, Shackebaei D, Yarmohammadi F Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(11):8367-8381.

PMID: 38850306 DOI: 10.1007/s00210-024-03207-3.


Post-translational modifications and immune responses in liver cancer.

Wang Y, Zuo J, Chen C, Li X Front Immunol. 2023; 14:1230465.

PMID: 37609076 PMC: 10441662. DOI: 10.3389/fimmu.2023.1230465.


PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.

Glaviano A, Foo A, Lam H, Yap K, Jacot W, Jones R Mol Cancer. 2023; 22(1):138.

PMID: 37596643 PMC: 10436543. DOI: 10.1186/s12943-023-01827-6.


The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer.

Oseni S, Naar C, Pavlovic M, Asghar W, Hartmann J, Fields G Cancers (Basel). 2023; 15(12).

PMID: 37370720 PMC: 10296711. DOI: 10.3390/cancers15123110.